key: cord-0845043-sm0112e3
authors: Jankelson, Lior; Karam, Giorgio; Becker, Matthijs L.; Chinitz, Larry A.; Tsai, Meng-Chiao
title: QT prolongation, torsades de pointes and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: a systematic review
date: 2020-05-11
journal: Heart Rhythm
DOI: 10.1016/j.hrthm.2020.05.008
sha: e8378ec07443ac458dd0aa00afbdb43b9ad3d923
doc_id: 845043
cord_uid: sm0112e3

Chloroquine and hydroxychloroquine are now being widely used as treatments for COVID-19. Both medications prolong the QT interval and accordingly may put patients at increased risk of torsades de pointes and sudden death. Published guidance documents vary in their recommendations for monitoring and managing these potential adverse effects. Accordingly, we set out to conduct a systematic review of the arrhythmogenic effect of short courses of chloroquine or hydroxychloroquine. We searched in MEDLINE and Embase, as well as grey literature up to April 17, 2020, on the risk of QT prolongation, torsades, ventricular arrhythmia, and sudden death with short-term chloroquine and hydroxychloroquine usage. This resulted in 390 unique records, of which fourteen were ultimately selected for qualitative synthesis and which included data on 1515 COVID-19 patients. Approximately 10% of COVID-19 patients treated with these drugs developed QT prolongation. We found evidence of ventricular arrhythmia in two COVID-19 patients out of a group of 28 treated with high-dose chloroquine. A limitation of these results is unclear follow-up and possible publication/reporting bias, but there is compelling evidence that chloroquine and hydroxychloroquine induce significant QT interval prolongation and potentially increase the risk of arrhythmia. Daily ECG monitoring and other risk mitigation strategies should be considered in order to prevent possible harms from what is currently an unproven therapy.

The aminoquinoline drugs chloroquine and hydroxychloroquine are now in increased 57 use globally as a potential, albeit unproven, treatment option for COVID-19. Regimens 58 vary but are generally equivalent to 400 to 1200 mg hydroxychloroquine (250 to 1000 59 mg chloroquine phosphate) per day for approximately five days. 1 However, these 

[ Figure 1 here] Our search yielded 390 unique records, of which 41 were eligible for full-text review. Of 123 those, eleven were included in the systematic review, along with an additional three 124 identified via reference tracking ( Figure 1 ). Study characteristics are given in Table 2 , 125 and outcomes summarized in Table 3 .

[ In COVID-19 patients, QT data was given in six studies (n = 318), which includes three 135 pre-prints (n = 210) and three publications (n = 108). 21,24,25 In a cohort of 84 136 hospitalized patients treated with hydroxychloroquine and azithromycin, 21 QTc 137 increased from a mean baseline of 435 ms to a maximum of 463 ms after 3.6 days, with 138 approximately 12% developing a QTc > 500 ms, a known marker of high arrhythmic 139 risk. This study also noted that baseline QTc poorly predicted this outcome, and that In COVID-19, nine studies, reporting a mix of mild, moderate, and severe cases, Our study found data on short-term chloroquine or hydroxychloroquine use in two 164 indications: malaria and COVID-19. Through its use in malaria, chloroquine may in fact 165 be the drug to which humans have been most exposed and the resulting real-world experience suggests it is generally safe. 17,19 Although it did not provide more granular 167 data on arrhythmia or sudden death, in a recent unpublished pre-print, Lane and 168 colleagues studied the initial 30-day course of hydroxychloroquine in rheumatoid 169 arthritis, and showed no increase in overall cardiovascular mortality relative to control.

This external evidence was consistent with data from studies in malaria included in this 171 review.

However, attempting to apply these data to the current pandemic is limited by the 173 differences in the treated diseases. There is warrant for the concern that COVID-19 174 patients are a population particularly vulnerable to drug-induced long QT syndrome and Given these limitations, and considering that that the benefit of these agents is currently 235 unknown, it is especially important to take reasonable precautions to minimize possible 236 risk. As drug-induced QT prolongation was observed early in some included studies, 237 daily ECG monitoring should be considered in all patients regardless of baseline QTc, 238 particularly patients with other risk factors for torsades (see Table 1 ). Where a lack of Full-text articles excluded (n = 30) 13 wrong outcomes 12 wrong study design 3 wrong dose 2 wrong population Studies included in qualitative synthesis (n = 14)

Studies identified in references (n = 3) 20 Tables   Table 1: Risk factors for QT prolongation and torsades de pointes General risk factors Illness-related risk factors Congenital long QT syndrome 3 Hypokalemia 5 Use of multiple QT-prolonging medications 16 Hypomagnesemia 5 Female sex 3 Sepsis 16 Myocardial injury, ischemia, or heart failure 16 Renal impairment 16 Bradycardia (heart rate < 60 bpm) 5 Recent conversion from atrial fibrillation 3

chloroquine' or 'hydroxychloroquine').ti,ab

ventricular fibrillation or (ventric* adj1 fibrillat*) or (ventric* adj1 arrhythm*)).mp

covid-19 or coronavirus or sars-cov-2).ti,ab

Embase Search Strategy #1. 'chloroquine':ti,ab OR 'hydroxychloroquine':ti,ab #2

heart ventricle fibrillation'/exp OR ('ventric*' NEXT/1 'fibrillat*') OR ('ventric*' NEXT/1 'arrhythm*')

heart arrest'/exp OR 'cardiac arrest' #5. 'qt' OR 'qtc' #6. 'torsade des pointes'/exp OR 'torsad*' #7

Full-text articles excluded (n = 30) 13 wrong outcomes 12 wrong study design 3 wrong dose 2 wrong population Studies included in qualitative synthesis (n = 14)Studies identified in references (n = 3)